Ecallantide: complete guide

Ecallantide is a 60-amino-acid plasma kallikrein inhibitor approved by FDA as Kalbitor in 2009. This guide covers its structure, mechanism, labeled use, trials and warnings.

Complete guide4 min read

Key takeaway

FDA approved ecallantide as Kalbitor on December 1, 2009. It is a chain of 60 amino acids with a molecular weight of 7,054 Da. Its boxed warning covers anaphylaxis, which the label reports in 4% of patients with hereditary angioedema in clinical studies.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the approval of Kalbitor on December 1, 2009.” (this article)
ClassImmune & inflammation
Body systemsImmune system
Studies cited1 in this article · 1 across 1 article on Ecallantide
Related productsBPC-157, TB-500 and thymic peptides

Ecallantide is a 60-amino-acid recombinant protein that blocks plasma kallikrein, the enzyme that releases bradykinin during hereditary angioedema attacks. This guide covers its structure, mechanism, FDA-labeled use, pivotal trials and label warnings. Sources were checked on November 17, 2026.

Quick answer: Ecallantide is a prescription plasma kallikrein inhibitor sold as Kalbitor. Its label covers acute attacks of hereditary angioedema (HAE) in patients 12 years and older. It carries a boxed warning for anaphylaxis. Two placebo-controlled trials, EDEMA3 and EDEMA4, supported approval.

Vitrapep does not sell ecallantide; this page is a reference summary of published research and regulatory information.

What is ecallantide?

The Kalbitor label states: “Ecallantide is a 60-amino-acid protein produced in Pichia pastoris yeast cells by recombinant DNA technology” (Kalbitor label, 2025). Recombinant means the gene for the chain is placed in yeast, which then makes it.

Elsewhere the label calls ecallantide “a small protein (7054 Da).” At 60 amino acids, it sits near the border between a long peptide and a small protein. Our peptide vs protein explainer and peptide primer cover where that line falls. PubChem lists the formula as C305H442N88O91S8 and the molecular weight as 7,054 g/mol (PubChem CID 44152182).

Drugs@FDA lists Kalbitor as a biologics license application (BLA 125277), approved on December 1, 2009, to Dyax Corp (Drugs@FDA). The current DailyMed label is from Takeda Pharmaceuticals America.

Table 1

Ecallantide: key facts

Fact Detail
Structure type 60-amino-acid recombinant protein made in Pichia pastoris yeast
Class Plasma kallikrein inhibitor
Molecular formula C305H442N88O91S8
Molecular weight 7,054 g/mol (7,054 Da)
First FDA approval December 1, 2009 (Kalbitor, BLA 125277)
Brand names (US) Kalbitor

How does ecallantide work?

Hereditary angioedema causes repeated attacks of swelling. The Kalbitor label explains the chemistry. Normally, a protein called C1 inhibitor (C1-INH) keeps plasma kallikrein in check. In HAE, C1-INH activity is low. During attacks, “unregulated activity of plasma kallikrein results in excessive bradykinin generation.”

The label says the excess bradykinin contributes to the swelling, inflammation and pain of an attack. It calls ecallantide a “selective, reversible inhibitor of plasma kallikrein.” By blocking kallikrein, it stops the conversion of high molecular weight kininogen to bradykinin. Icatibant works one step later: it blocks the bradykinin B2 receptor instead of bradykinin production.

What is ecallantide approved for?

The Kalbitor label lists one indication: “treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older.” The label covers treatment of attacks; it does not list prevention.

The label lists one contraindication: known clinical hypersensitivity to Kalbitor.

What did the key trials show?

The label describes two placebo-controlled human trials, EDEMA3 and EDEMA4, in 168 patients with HAE. Some patients took part in both, for 143 unique patients.

EDEMA3. This double-blind trial randomized 72 patients with an acute HAE attack to ecallantide or placebo. The primary end point was a treatment outcome score at 4 hours, which rates change in symptoms. The median score was 50.0 with ecallantide and 0.0 with placebo (P=0.004) (Cicardi et al., 2010). It is registered as NCT00262080.

EDEMA4. This double-blind trial enrolled 96 patients (NCT00457015). Its primary end point was the change in mean symptom complex severity score at 4 hours. The label reports a greater decrease with ecallantide than with placebo. It gives a 4-hour treatment outcome score of 53 with ecallantide versus 8 with placebo.

What side effects does the label list?

The Kalbitor label has a boxed warning titled “Anaphylaxis.” It warns that the symptoms of an allergic reaction can look like an HAE attack, and that patients should be watched closely. In clinical studies of 255 HAE patients, 10 (4%) had anaphylaxis. The label says “these reactions occurred within the first hour.”

The most common adverse reactions (3% or more, and above placebo) were headache, nausea, diarrhea, fever, local site reactions and nasopharyngitis. The label also reports that 20.2% of patients developed antibodies to ecallantide. Patients who develop these antibodies may face a higher risk of hypersensitivity reactions.

What is ecallantide’s regulatory status, and how is it used in research?

Ecallantide is a prescription biologic in the United States, and Drugs@FDA lists Kalbitor as a prescription product. The label was last revised in June 2025.

Research beyond HAE has been clinical, not laboratory. ClinicalTrials.gov lists completed trials of ecallantide to reduce blood loss in cardiac surgery, such as CONSERV-2 (NCT00888940). It also lists a terminated trial in angioedema caused by ACE inhibitor drugs (NCT01343823). None of these uses is on the label. We found no documented role as a laboratory reagent.

Frequently asked questions about ecallantide

Is ecallantide a peptide or a protein?

It is a 60-amino-acid chain. The label calls it a small protein, but its size puts it near the line between peptides and proteins.

When was ecallantide approved?

Drugs@FDA lists the approval of Kalbitor on December 1, 2009.

What does ecallantide block?

Plasma kallikrein, the enzyme that cuts high molecular weight kininogen to release bradykinin.

How is ecallantide different from icatibant?

Ecallantide blocks bradykinin production. Icatibant blocks the receptor that bradykinin acts on. Both are labeled for acute HAE attacks.

Does ecallantide have a boxed warning?

Yes, for anaphylaxis. The label reports it in 4% of HAE patients in clinical studies.

What to know now

  • Structure: 60-amino-acid recombinant protein; 7,054 Da.
  • Approval: Kalbitor, December 1, 2009 (BLA); prescription only.
  • Mechanism: selective, reversible plasma kallikrein inhibitor that cuts bradykinin production.
  • Evidence: two placebo-controlled trials (EDEMA3 and EDEMA4) in 143 unique HAE patients.
  • Label: acute HAE attacks in patients 12 years and older.
  • Safety: boxed warning for anaphylaxis (4% in clinical studies).

What we’re watching

Further revisions to the Kalbitor label on DailyMed, last revised in June 2025. Related guides: icatibant, pegcetacoplan and bivalirudin.

More for immune system

All 24 compounds for immune system

Sources: Takeda Pharmaceuticals America 2025, KALBITOR (ecallantide) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: BLA 125277 (KALBITOR) . Retrieved November 17, Drugs@FDA: BLA 125277 (KALBITOR); National Center for Biotechnology Information 2026, PubChem compound summary for CID 44152182, ecallantide; Cicardi 2010, The New England Journal of Medicine, 363; Shire 2005, Efficacy and safety study of DX-88 to treat acute attacks of hereditary angioedema (HAE); Shire 2007; Cubist Pharmaceuticals 2009; Shire 2011. All 8 citations

Back to the research library

References

  1. Takeda Pharmaceuticals America, Inc. (2025). KALBITOR (ecallantide) prescribing information (revised 6/2025). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f56aec67-c662-477c-b866-bfc23e8809cf
  2. U.S. Food and Drug Administration. Drugs@FDA: BLA 125277 (KALBITOR). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125277
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 44152182, ecallantide. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/44152182
  4. Cicardi, M., et al. (2010). Ecallantide for the treatment of acute attacks in hereditary angioedema. The New England Journal of Medicine, 363(6), 523–531. https://doi.org/10.1056/NEJMoa0905079
  5. Shire. (2005). Efficacy and safety study of DX-88 to treat acute attacks of hereditary angioedema (HAE) (ClinicalTrials.gov ID NCT00262080). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT00262080
  6. Shire. (2007). Efficacy study of DX-88 (ecallantide) to treat acute attacks of hereditary angioedema (HAE) (ClinicalTrials.gov ID NCT00457015). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT00457015
  7. Cubist Pharmaceuticals. (2009). Outcomes and safety trial investigating ecallantide’s effect on reducing surgical blood loss volume in subjects at high risk of bleeding exposed to cardio-pulmonary bypass during cardiac surgery (CONSERV-2; ClinicalTrials.gov ID NCT00888940). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT00888940
  8. Shire. (2011). Evaluation of ecallantide for treatment of angiotensin converting enzyme (ACE) inhibitor induced angioedema (ClinicalTrials.gov ID NCT01343823). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT01343823